Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · IEX Real-Time Price · USD
1.250
+0.040 (3.31%)
At close: Mar 28, 2024, 4:00 PM
1.270
+0.020 (1.60%)
After-hours: Mar 28, 2024, 7:39 PM EDT
Company Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors.
The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021.
Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Achilles Therapeutics plc
Country | United Kingdom |
Founded | 2016 |
IPO Date | Mar 31, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 234 |
CEO | Dr. Iraj Ali Ph.D. |
Contact Details
Address: 245 Hammersmith Road London, X0 W6 8PW United Kingdom | |
Phone | 44 (0)20 8154 4600 |
Website | achillestx.com |
Stock Details
Ticker Symbol | ACHL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001830749 |
CUSIP Number | 00449L102 |
ISIN Number | US00449L1026 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Iraj Ali Ph.D. | Chief Executive Officer and Director |
Dr. Karl Stuart Peggs M.D. | Founder and Chief Medical Officer |
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder |
Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder |
Dr. Sergio A. Quezada Ph.D. | Founder and Chief Scientific Officer |
Robert Coutts | Chief Financial Officer |
Lee M. Stern | Vice President of Investor Relations and External Communications |
Daniel Carey Cazel Hood | General Counsel and Company Secretary |
Julia Wilson | Head of Communications |
Tariq Ahmed | Executive Vice President of People |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 1, 2024 | 144 | Filing |
Nov 13, 2023 | 6-K | Report of foreign issuer |
Nov 1, 2023 | 144 | Filing |
Sep 22, 2023 | 6-K | Report of foreign issuer |
Aug 17, 2023 | 144 | Filing |
Aug 4, 2023 | 6-K | Report of foreign issuer |
Jun 29, 2023 | 6-K | Report of foreign issuer |
May 10, 2023 | 6-K | Report of foreign issuer |